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1. Introduction – Historical review of inhalation 
for drug delivery
The substantial progression witnessed in the de-
velopment of inhalation devices may indicate that 
pulmonary drug delivery is a novel route of ad-
ministration. However, the use of treatments 
through inhalation for therapeutic intents has ex-
isted for thousands of years and has been prac-
tised in numerous civilizations (Figure 1). Four 
thousand years ago, in India, pulverized jimson-
weed (Datura stramonium) and angel’s trumpet (Da-
tura ferox) were mixed with natural ingredients 
such as pepper or ginger and smoked for their 
bronchodilating therapeutic properties, due to 
their alkaloids content [1, 2]. Apart from that, the 
oldest known mention of the use of inhalation for 
therapeutic purposes dated back to 1554 BC and 
was found in the Ebers papyrus. In this Egyptian 
papyrus scroll, a depiction of patients who seem to 
have trouble breathing can be found. Black hen-
bane (Hyoscyamus niger) is put on hot bricks, and 
the vapour generated is respired by the patients 
through a stem of reed attached to a pot placed 
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Figure 1 Timeline of the History of inhalation therapy
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over the burning plant. Hyoscyamus niger’s reme-
dial properties come from its tropane alkaloids 
contents, particularly atropine and its anticholin-
ergic properties [3]. 
In 1100 BC, opium was smoked using pipes and 
incense burners for both therapeutic and recreation-
al purposes in China. This marks one of the most 
notable uses of the pulmonary route of administra-
tion, although Avicenna thoroughly detailed opi-
oids’ toxicity and dissuaded their usage [3].
In 600 BC, a description of the treatment of asth-
ma by therapeutic inhalation was detailed in the 
scriptures of Charaka and Sushruta (notorious In-
dian physicians). Datura stramonium (which con-
tains atropine) was used against asthma symptoms, 
in the form of a cigarette or a pipe. In his writings, 
Charaka also describes steam inhalation and cigars 
(made of several natural ingredients such as the 
paste of turmeric) as asthma therapies [3].
In the second century AD, Galen suggested the 
use of powders of myrrh and nutgall through in-
halation to reduce nasal and chest symptoms [3].
From the Middle Ages most therapies were 
based on the methods developed during the An-
cient Times such as the smoking of opium or Da-
tura stramonium. One of the most groundbreaking 
approaches of the Middle Ages was made by the 
Arab physician Rhazes. He developed a liquid 
mixture of narcotic plants: opium, mandrake, and 
henbane. A sponge was then soaked in the solu-
tion and left to dry. Before surgery, the sponge 
was humidified and placed on the patient’s mouth 
and nose. The patient would then inhale the 
fumes generated by the sponge. These vapours 
produce an anaesthetic effect [3].
With the start of the Industrial Revolution 
(1760-) came significant innovations, notably in 
manufacturing procedures. The respiratory drug 
delivery acquired a particular attention when the 
English physician Philip Stern declared that “the 
only possible way of applying medicines directly 
to the lung is through the windpipe”. The inhalers 
created by Stern and English physician John 
Mudge amplified the popularity of the treatment 
of asthma through the inhalation of pharmaceuti-
cal drugs [1, 4, 5]. As a consequence, various ce-
ramic inhalers were developed. 
When it comes to drug inhalation, the therapeu-
tic aerosol had to be prepared by either the physi-
cian or the patient himself. However, during the 
Industrial Revolution, the discoveries and advanc-
es made allowed for the aerosol to be made by a 
third party and even to be produced on a large 
scale. Furthermore, novel entities and techniques 
were designed, allowing for the active ingredient 
to be isolated, and its safety and potency to be im-
proved. The Industrial Revolution era also marks 
the launch of nebulizers and early versions of dry 
powder inhalers (DPIs) [3].
The early 1900s were marked by the popularity 
of hand-bulb nebulizers delivering adrenaline 
chloride for its bronchodilating properties. In the 
20th century, new types of nebulizers were devel-
oped: the electric and the ultrasonic nebulizers [1].
The period between 1956 and 1986 brought the 
advances of pressurized metered-dose inhalers 
(MDIs) and later the dry powder inhalers which 
are still broadly used presently. The introduction 
of metered-dose inhalers (MDIs) started in 1956 
[1, 2], among the first approved MDIs was the Me-
dihaler-Ergotamine, a device delivering ergota-
mine tartrate for migraine therapy, which illus-
trates the early interest for the therapy of systemic 
conditions through the pulmonary route of ad-
ministration [6]. Supplementary devices were also 
developed to ameliorate the efficacy of the inhal-
ers and to facilitate patient coordination. Two 
DPIs, in particular, marked this period: the Spin-
haler® and the Rotahaler®. The Spinhaler® deliv-
ered 20 mg of sodium cromoglycate [1] from a 
gelatin capsule which is later on pierced by the 
device. The formulation aspects of this inhaler 
shaped the present formulation development of 
DPIs. The Rotahaler® delivered albuterol from a 
capsule which is later halved by the device [3].
The latest period since 1987 (marked by the sig-
nature of the Montreal Protocol eliminating CFC 
propellants) is characterized by a recordbreaking 
advancement in the pulmonary drug delivery with 
the rise of yearly sales from $7 billion in 1987 to 
$36 billion in 2014 [3]. In 2002, the introduction of 
Advair®/Seretide® delivering salmeterol xinafoate/
fluticasone propionate for the treatment of asthma 
resulted in the first multibillion- dollar DPI. An-
other example is the Spiriva® inhaler launched in 
2004, delivering tiotropium. It was the first inhala-
tion drug intended for the treatment of COPD 
(Chronic Obstructive Pulmonary Disease), which 
at the time was an inefficiently treated disease [6].
2. Advantages of pulmonary drug delivery
The pulmonary delivery is an interesting drug de-
livery route for locally acting treatments of lung 
diseases such as asthma. However, owing to the 
scientific development of pharmaceutical formula-
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tions and inhalation devices, pulmonary drug de-
livery plays an important role in delivering drugs 
systemically and treating systemic conditions such 
as diabetes, certain autoimmune diseases and 
some types of cancer [7]. Pulmonary delivery can 
be obtained via oral or nasal routes. However, 
higher drug deposition can be achieved with the 
former way. This can be attributed to the physio-
logical structure of the human lungs. The respira-
tory tract has two distinct parts by function: the 
respiratory zone and the conducting airways [8]. 
According to Weibel’s lung model – which is the 
simplest and widely used model – there are 23 so-
called generations (G) and the trachea (G0) (Figure 2) 
[9]. The evolution starting from the trachea to the 
alveolar ducts can be described by decreased tube 
length and cross-sectional tube area, yet an in-
creased number of tubes. In the lumen, the trachea 
has a width of approximately 2.5 cm while the al-
veolar ducts possess a diameter of only 0.2–0.5 
mm. Thereby the airways have a surface area of 
about 2.5 m2, and that of the alveoli is about 100 
m2. The mouth and nasal cavities, pharynx and 
larynx, also belong to the conducting zone and are 
responsible for carrying the gas to the site of the 
gas exchange, as well as filter, warm up and hu-
midify the inspired air. The gas exchange occurs 
from the respiratory bronchioles (G17) to the alve-
olar sacs (G23) [8, 10].
Due to their physiological properties, namely a 
large surface area beneficial for absorption (100 m2), 
the lungs possess a unique platform for drug de-
livery, whether locally or systematically. This also 
allows a rapid onset of action of drugs. There are 
no food effect or pH problems, and the first-pass 
metabolism can be avoided. Consequently, a de-
creased effective dose can be used, and fewer side 
effects could occur. 
3. Inhalation devices
The painless drug delivery - compared to injec-
tions - could increase the patient’s compliance. 
However, it is necessary to inform them about the 
proper manipulation of the inhalation devices. Up 
to 50% of the patients misuse the inhalers due to 
the incoordination of the inhalation with the actu-
ating element. Three main types of devices are 
available on the market: nebulizers, pressurized 
metered-dose inhalers (pMDIs) and dry powder 
inhalers (DPIs) (Figures 3-5) [8].
Aerosols are solutions or suspensions, where 
the active ingredient (in a liquid or solid- state) is 
suspended in a carrier gas, intending to deliver the 
drug to the alveoli. Nebulizers can transform the 
solution or suspension into small droplets based 
on different working mechanisms (jet, ultrasonic 
and mesh). They consist of a medication reservoir, 
a baffle compressor, a mouthpiece and a facemask. 
The general disadvantages of nebulizers are the 
high cost, difficulty in cleaning the device and the 
fact that drug wastage could occur. Moreover, 
electricity is necessary for the ultrasonic devices. 
On the other hand, they are easy to use, the con-
tamination could be reduced, and they are more 
efficient when it comes to delivering active ingre-
dients which cannot be delivered with the other 
devices. 
Pressurized metered dose inhalers (pMDIs) are the 
most frequently prescribed devices for asthmatic 
or COPD patients. Single-dose and multi-dose de-
vices are accessible on the market, consisting of 
drug concentrate, propellant, metering valve and 
actuator. The main benefit of pMDIs is that the 
aerosol is formed by atomizing the extremely vol-
atile propellant which is used to deliver an exact 
dose within a short treatment time. They are small 
and portable with a dose counter; therefore the pa-
tient can easily follow the therapy. Figure 2 Weibel’s lung model (based on [8])
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Soft Mist inhalers (SMIs) are MDIs, which are 
propellant-free. In order to produce an inspirable 
aerosol from a solution, the liquid dose needs to 
have a suitable droplet size. This can be achieved 
through two main methods: a first approach is the 
use of vibrations created by electrical energy (ul-
trasonic and piezoelectric devices). Another meth-
od would be pushing the solution through a noz-
zle using a mechanical 
force. An example of that 
is the Respimat® SMI (Fig-
ure 6), which functions by 
using the mechanical en-
ergy of a string com-
pressed by the patient 
[11, 12]. 
Another example of 
SMIs is the AERx Es-
sence® (Aradigm Corp.) 
which uses a breath-actu-
ated piston system to 
push the solution through 
a nozzle arrangement, 
and a heating system to 
decrease the droplet size. 
A small screen incorpo-
rated to the device pro-
vides visual feedback to 
the patient. AERx Es-
sence® is used for the pul-
monary administration of 
insulin [12-14].
Dry powder inhalers 
(DPIs) are propellant-free 
devices, containing frac-
tionated and a micronized 
powder formulation of 
drugs. When a patient 
uses their inhaler, their in-
spiratory airflow constitutes the principal driving 
force for delivering breathable particles in dry 
powder to the deep lung. DPI devices contain the 
powder formulation, a dose-measuring system 
and a mouthpiece. The main advantages are that 
they are propellant-free, portable and require a 
short treatment time. However, the main disad-
vantages could be the dependence on the inspira-
Figure 3 Types of inhalation devices
Figure 6 Respimat® Soft mist 
inhaler
Figure 4 Examples of conventional pMDIs: Ventolin Evohaler, Serevent Evohaler, Foster, 
and Atimos
Figure 5 Examples of passive DPIs: Breezhaler, Symbicort Turbuhaler, Pulmicort 
Turbuhaler, Handihaler, Foster Nexthaler, Ellipta, and Seretide Diskus
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tory flow of the patient and the particle aggrega-
tion due to humidity [8, 10]. A study using an in-
vitro-in-silico procedure was performed on several 
DPI formulations placed in a highly humid envi-
ronment. This study examined how these DPI for-
mulations could influence a treatment when 
placed in a high humidity environment, alongside 
patients’ wrong storage of the inhalers. The DPIs 
used were Easyhaler® and Novolizer®, both con-
taining budesonide and lactose. It concluded that 
formulations with smaller particle size and a high-
er quantity of excipient fines are more likely to be 
sensitive to humidity, which makes their efficiency 
inconstant after their storage [15]. This is particu-
larly pertinent and problematic, considering that a 
significant amount of patients store their inhalers 
in unsuitable and highly humid conditions [16]:
 − 42% of patients store their inhaler in a bath-
room
 − 21% in their pocket or a handbag
Concerning patients’ errors, there are current 
trends which aim to face this challenge, such as 
smart devices. These devices are developed using 
electronic monitoring systems that can connect to 
other devices or even to an internet network.  The 
goal is to decrease the errors made by both the pa-
tients and the devices, as well as to enhance the 
patients’ compliance with inhalation therapy. 
These devices possess the ability to track the pa-
tients’ adherence, as well as their use of the inhal-
er. The set goals are reached through characteris-
tics such as a reminder which prompts the patient 
to take the dose, or even by providing the patient 
with a guide displayed on the inhaler’s screen ex-
plaining the use of the inhaler step by step [17]. 
There are two different types of smart inhalers: 
“add-on” devices and “originally integrated” de-
vices. An example of the originally integrated de-
vices is the 3M™ Intelligent Control Inhaler by 
3M™ Drug Delivery Systems [18].
4. Appropriate inhaler use and supplementary 
devices
Managing respiratory conditions such as  asthma 
and COPD depends significantly on the proper 
use of the inhaler provided for the therapy. Incor-
rect use of the device or a faulty inhalation rou-
tine can reduce the drug delivery and therefore 
affect the disease control. A study conducted in 
France by Molimard et al. showed that out of over 
3800 outpatients, 76% made a least one mistake 
while using a pMDI [19]. 
Even with the vast choice of devices available 
on the market and their level of precision, deliver-
ing an accurate dose can still be challenging some-
times. Moreover, when incorrectly using a pMDI, 
a poor drug deposition in the lungs occurs, result-
ing in a high oropharyngeal drug deposition [20-
22]. Consequently, spacers (also referred to as 
holding chambers or extension devices) can be 
used. Spacers are supplementary devices which 
improve the performance of an inhaler. They 
work by keeping the medication in an enclosed 
space during the inhalation. The use of a spacer 
added to a satisfactory inhalation technique can 
improve the drug delivery by up to 5-10% [23]. A 
study organized in India showed that out of 300 
patients, 247 (82.3%) made a mistake while using 
their inhaler. Out of these 247 patients, the highest 
number of errors was noted in patients using 
MDIs (94.3%). However, patients who used a 
spacer with their MDIs resulted in a smaller per-
centage (78%). Some of those errors were: “Inhaler 
not shaken” (40%), “Long delay before inhalation” 
(36%), and “Stopping inhalation as the device is 
fired” (32%) [24]. Thus, spacers not only reduce 
oropharyngeal deposition, but they also decrease 
the accuracy demand for the actuation and inhala-
tion while using a pMDI on its own [25]. This is 
particularly advantageous in infants and children 
since they are unable to produce an accurate in-
spiratory manoeuvre or refuse to cooperate. It is 
also recommended to use facemasks, especially in 
infants [22, 23]. Moreover, the use of spacers and 
facemasks is also helpful and convenient for pa-
tients who require medical assistance, such as el-
derly patients with COPD and cognitive impair-
ment [25, 26]. It has to be noted that spacers and 
facemasks are likely to be exposed to contamina-
tion by microorganisms. Since they are exposed 
and get in contact with mucous membranes, it is 
recommended they undergo cleaning, disinfec-
tion, rinsing, and air-drying after each use [27]. 
However, this cleaning procedure required after 
each use is not executed nor supported or en-
dorsed by the manufacturers and the instructions 
leaflets they provide. Even so, it is advisable, at 
the very least, not to share spacers between pa-
tients [28].
In veterinary medicine, - proper use of spacers 
and facemasks can be observed to improve the 
therapy by optimizing the actuation. Since animal 
and human facial characteristics are not similar, a 
facemask constitutes an essential junction between 
the animal and inhalers such as nebulizers or 
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pMDIs [29]. Moreover, contrary to humans, it is 
quite troublesome to control the breathing pattern 
of animals. In horses, for example, it is inconceiv-
able to inquire a voluntary deep breath. Using an 
extension device such as spacers and facemasks al-
lows the adaptation of commercially available hu-
man pMDIs to horses. Nebulizers could also be 
used, but unlike pMDIs with spacers, nebulizers 
permit the deposition of only small amounts of a 
drug in the equine lungs. In this regard, the utiliza-
tion of pMDIs with a spacer in the veterinary prac-
tice is thought to be a great advance [30]. In case 
the horse reacts to the sound of the pMDI’s actua-
tion, there is a possibility for the inhaler to be actuat-
ed in the spacer, away from the horse’s face. The 
chamber can then be placed on the horse’s face, held 
up to the nostril, until the next inhalation. Examples 
of inhaling devices used for horses are Equine Haler 
and AeroHippus. (Figures 7 and 8) [30]. 
5. Inhalation as an alternative delivery route
5.1. Prospects and innovative developments
Inhalation as a delivery route finds its pertinence 
in the advantageous properties of the lungs (high 
permeability, large surface area). Moreover, an el-
evated local drug concentration can be obtained 
through pulmonary delivery, which is then rapid-
ly absorbed through the alveoli, thus allowing a 
fast onset of action while at the same time still 
keeping systemic adverse effects to the minimum. 
The use of inhalation prevents specific gastroin-
testinal issues such as food effects, gut irritability, 
undesired metabolites, and poor solubility [31]. 
Furthermore, due to the absence of the first-pass 
metabolism, inhalation constitutes a great alterna-
tive to drug formulations, which cannot be deliv-
ered orally [32]. In addition, it also represents an 
excellent substitute for drug formulations, which 
are administered through an invasive method. 
Numerous macromolecules present in different 
stages of clinical development are listed in Table I. 
Similarly, examples of various small molecule in-
halation products present in clinical development 
are listed in Table II [33].
There is also a possibility for vaccination 
through pulmonary delivery. Back in 1958 al-
ready, the possibility of vaccination via inhalation 
was suspected: a quite small number of living at-
tenuated Mycobacterium tuberculosis (fewer than 25 
infective units per animal) effectively induced im-
munity against airborne infection with virulent 
bacilli in guinea pigs [34].
Another example of this is Spiros® (developed 
by Dura Pharmaceuticals Inc.), a measles vaccine 
which is administrable using a DPI. Regrettably, it 
Figure 7 Sketches of the veterinary Equine Haler and 
AeroHippus devices
Figure 8 Inhaling mask for horses
Table I Examples of macromolecules in clinical development (based on [33])
Macromolecule(s) Targeted condition
GLP- 1 and insulin Type 2 diabetes
PTH (parathyroid hormone) and salmon calcitonin Osteoporosis
Erythropoeitin Anemia
Interferons Multiple sclerosis
Growth hormone (GH) Growth deficiencies
Plasmid complex gene delivery Hemophilia
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was not successfully marketed. One of its weak-
nesses was that in case of flat batteries, it was 
prone to failure. Besides, the intricacy of the de-
vice led to its expensiveness [1, 35].
A liposomal inhalation formulation has also 
been developed and FDA-approved for Amikacin, 
an aminoglycoside antibacterial drug. Arikayce® 
(ALIS - Amikacin liposome inhalation suspension) 
is a suspension administered once daily using the 
Lamira™ Nebulizer System. Amikacin is encapsu-
lated in small liposomes (with a diameter of ap-
proximately 300 nm) containing dipalmitoylphos-
phatidylcholine (DPPC) and cholesterol in a high 
drug-to-lipid ratio. It is used for the treatment of 
MAC (Mycobacterium avium complex) lung disease 
in a combination treatment for patients for whom 
the standard therapy has not been successful and 
whose substitute therapies are limited or unavail-
able. It has been shown that ALIS considerably 
improved the chances of obtaining sputum cul-
ture conversion when used as an add-on to guide-
lines-based therapy (GBT) compared to the use of 
GBT alone [36, 37].
5.2. Insulin administration through pulmonary 
delivery
Since the discovery of insulin in 1921-1922 at the 
University of Toronto [38], there has been a per-
manent search for a non-injectable yet effective 
route of administration. In 1987, a study was con-
ducted on six diabetic children where semi-syn-
thetic human insulin was administered via the 
pulmonary route using a nebulizer. The conclu-
sion was that the blood glucose control gathered 
was at least as satisfactory as the one obtained fol-
lowing the administration of the regular dose of 
subcutaneous insulin [39]. Nevertheless, it was ac-
knowledged that inhaled insulin had a consider-
ably reduced bioavailability compared to that of 
the subcutaneous insulin. Thus, inhaled insulin 
reached clinical studies only after the delivery de-
vices available, and particle pharmacology 
reached a certain advancement [40].
The oral and the nasal routes have been the most 
researched, but none of them ended up in a sustain-
able product due to the low and inconstant bioavail-
ability. These issues are mostly due to the imperme-
ability of the nasal and gastrointestinal epithelia to 
insulin. This unsuccessfulness led to the investiga-
tion of the pulmonary route since the lungs are nat-
urally permeable to some proteins [41].
Fourteen short studies conducted on both healthy 
and diabetic patients investigated inhaled regular, 
soluble insulin as early as in 1925. Additionally, in 
all studies, a decrease in blood glucose was noted, as 
well as a considerable absorption of insulin. These 
events were obtained without the help of penetra-
tion enhancers. Moreover, despite early stu dies ap-
prehensions concerning variable dosing, it has been 
guaranteed that the inhaled insulin’s variability can 
be equally as good, if not higher than the subcutane-
ously injected insulin [41].
An example of inhalation insulin was Exubera® 
(developed by Pfizer Inc.). It was approved by 
both the FDA (Food and Drug Administration) 
and the EMEA (European Medicines Agency) for 
the treatment of type 1 and type 2 diabetes. It was 
a DPI which operated using blisters of 1 mg or 3 
mg of regular human insulin [40]. The greater part 
of the formulation was insulin (about 60%). The 
excipients present consisted mainly of a stabilizer 
(mannitol) [42]. The device consisted of active 
powder dispersion by pressurized air obtained 
from a hand piston. Unfortunately, it has not been 
successfully marketed due to its cost, but also its 
significant number of operational steps required, 
and its large size. Insulin requires several admin-
istrations, notably in public. Therefore it is highly 
required for the device used to be convenient and 
discreet [1, 43]. In 2007, weak sales and poor ac-
ceptance of the inhaler prompted Pfizer to discon-
tinue the diabetes drug [6, 40].
A new inhaled insulin example is Afrezza®, an 
FDA-approved ultra-rapid acting insulin aiming 
to enhance postprandial glycemic control in dia-
betic patients, inhaled using a DreamBoat™ inhal-
er [44]. The administration of Afrezza® is ensured 
to be secure and effective in type 1 diabetic pa-
tients [45].
Table II Examples of small molecules in clinical development (based on [33])
Small molecule Targeted condition
Dihydroergotamine Migraine
Fentanyl citrate Breakthrough pain in cancer
Apomorphine Male and female sexual diseases
Nicotine Smoking cessation
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6. Drug deposition and absorption in the lungs
Particle deposition is the first step after inhalation. 
It can occur in the lungs by three main mecha-
nisms: inertial impaction, sedimentation and dif-
fusion. Other mechanisms are an interception and 
electrostatic precipitation which are related to the 
particle shape and the electrostatic charges [9, 46]. 
The deposition mechanisms in the lungs are dem-
onstrated in Table III.
Inertial impaction is the principle deposition mech-
anism in the 1-10 generations of the lungs due to the 
elevated air velocity with the turbulent flow. Larger 
molecules (above 5 μm) tend to move out with the 
air stream and impact the wall of the upper airways. 
The properties of particles, such as density and di-
ameter play a significant role in this case. 
Sedimentation is the time-dependent effect on 
the particles with 0.5-5 μm size in the deeper lung 
(bronchi, bronchioles and alveolar region) where 
the velocity decreases.  The gravitational force 
causes the deposition of the particles and is de-
rived by particle diameter, mass, residence time 
and decreased flow rate. Particles of 3-5 μm reach 
the tracheobronchial region with sedimentation. 
Sedimentation and diffusion are expected in case of 
particles with a size of 0.5-3 μm which are able to 
reach the alveolar region.
In the alveolar region, particles with a size 
smaller than 0.5 μm will deposit according to the 
diffusion principle due to the Brownian motion. 
Nevertheless, due to their significantly small size, 
the majority of the particles are exhaled and mere-
ly few of them deposit.
Direct interception is a phenomenon which usu-
ally occurs in case of particles with elongated 
shape in the upper airways, while charged parti-
cles are prone to undergo electrostatic deposition [9].
The fate of particles after inhalation depends on 
the physiology of the patients and the aerosol 
properties of the particles, namely size, size distri-
bution, shape, charge, density and hygroscopicity 
[10, 46]. It is well established (Table III) that the 
size of particles has an important significance in 
the particle deposition. There are two main calcu-
lable parameters which express the aerodynamic 
properties of aerosols: the mass median aerody-
namic diameter (MMAD) and the geometric stan-
dard deviation (GSD). MMAD is a diameter which 
is calculated based on the mass distribution and 
divides particles into two parts: 50% of the aerosol 
is larger, the remaining 50% is smaller.  If the 
MMAD is between 0.5 μm and 5 μm, the aerosol 
is usually considered breathable. The ideal size for 
a deep lung deposition is 2-3 μm. The GSD dem-
onstrates the variance within the particles, in 
which the values of 1 and above 1.2 indicate mo-
no-disperse and hetero-disperse systems [10]. 
Spherical-shaped particles are the most preferred 
and could easily be manufactured. However, elon-
gated particles are gaining attention due to the 
lung penetration of fibers. Generally, low-density 
particles with a  large geometric diameter have 
better aerodynamic properties than high-density 
particles with a small geometric diameter [10]. 
There are strategies to alter the aerodynamic di-
ameter (Dae). These are based on the following 
equation (1), where Deq is the diameter of an 
equivalent volume sphere of unit density,  ρp and 
ρo are particle and unit densities, and X is the dy-
namic shape factor  [47]:
 (1) 
Both large and porous or needle-shaped parti-
cles are presumed to have a smaller aerodynamic 
diameter than their particle size would suggest 
[47]. All of these parameters aside, the surface 
charge and the hygroscopicity are also important 
physicochemical properties. While the surface 
charge of the cell membrane is negative, small 
particles with a positive charge can bind easily. 
However, the mucus layer of  the lung epithelium 
acts as an absorption barrier due to its adhesive 
surface; therefore it may hinder the penetration of 
even charged particles [48]. Hygroscopic materials 
should be formulated carefully in case of DPIs due 
to the proneness to aggregation [46]. 
Table III Deposition mechanisms in the lung (based on [9])
Particle size Mechanism Parts of Respiratory tract
Above 5 μm Inertial impaction Oropharynx and conducting airways
0.5 – 5 μm Sedimentation
Bronchi, Bronchioles and Alveoli
0.5 – 3 μm Sedimentation and Diffusion
Below 0.5 μm Diffusion and Brownian motion Alveolar region
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Drug absorption in the lung is also influenced 
by the physiological environment and clearance 
mechanisms. In the human lung, the dissolving 
medium volume is about 10-30 ml with a pH of 
about 6.6 and consists of 96% water. The remain-
ing 4% are electrolytes and proteins. The drug 
particles should be in a dissolved state in order to 
absorb, otherwise they might get cleared up by 
one of the clearance mechanisms. The principal 
clearance mechanism is the mucociliary clearance 
(MCC) which is derived by the synchronous 
sweeping movement of cilia and mucus on the 
surface of epithelial cells. Their function is the re-
moval of particles from the environment. There-
fore, with the propulsive movement of mucus to-
wards the larynx, the particles will be eliminated 
by swallowing or coughing out, generally within 
24 hours. The other possibility is the alveolar clear-
ance which is a defence mechanism against harm-
ful microorganisms and particles by macrophages. 
Particles with a size between 1.5 μm and 3 μm are 
more susceptible to phagocytosis, and the alveolar 
permeability is decreasing with increasing molec-
ular weight. There is  also a mechanical clearance for 
large particles (above 10 μm) which immediately 
induces coughing, sneezing or swallowing [9]. 
The metabolisms in the lungs are similar to the liv-
er. All of phase I metabolizing enzymes can be 
found in the lung, however, in lower quantities and 
CYP3A5 is expressed abundantly in the lungs [9].  
Figure 9 shows the correlation between the aero-
dynamic diameter (in μm) and the percentage of 
deposition in the lungs. The aerodynamic diameter 
is the diameter of a sphere with the same settling 
velocity as the particle of interest [50]. As mentioned 
before, large molecules with an aerodynamic diam-
eter higher than 5 μm tend to impact on the wall of 
the upper airways and get swallowed. Therefore, 
the particles with an aerodynamic diameter smaller 
than 5 μm are the ones with the highest potential 
for deposition in the lungs. In an aerosol, the ratio 
of these particles is referred to as either the fine par-
ticle dose (FPD) if it is expressed in absolute mass of 
drug in the particles that are smaller than 5 μm, or 
the fine particle fraction (FPF):
 − The FPD is the mass of particles smaller than 5 
μm present within the total emitted dose. 
 − The FPF is equal to the FPD divided by the total 
emitted dose.
The higher is the FPF in an aerosol, the higher is 
the probability of it depositing deeper in the 
lungs. Consequently, present inhaler devices pro-
duce aerosols containing a considerable percent-
age of particles between 1 and 5 μm [49].
7. Formulation of inhalation dosage forms
7.1. Excipients in the pulmonary drug delivery
The International Pharmaceutical Excipients 
Council (IPEC) characterizes excipients as sub-
stances in a pharmaceutical formulation other 
than the active pharmaceutical ingredients which 
“have been appropriately evaluated for the safety 
in order to help processing, manufacturing, pro-
tection, and give support or to enhance stability, 
bioavailability, or patient 
acceptability or to assist 
in product identification 
or improve any features 
of the safety or effective-
ness of the drug delivery 
system during storage or 
use.” [51]. When it comes 
to pulmonary drug deliv-
ery, excipients are partic-
ularly necessary in the 
formulation in order to 
achieve an optimal size, 
for instance. As a conse-
quence, excipients for in-
haled drugs are usually 
present in relatively high 
amounts compared to the 
active pharmaceutical in-
gredient. 
Figure 9 Relationship between particle aerodynamic diameter and lung deposition (based on 
[49])
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7.2. Formulations in the pulmonary drug delivery
As seen previously, the inhalation systems can be 
divided into three main types: nebulizers, pMDIs, 
and DPIs. 
Nebulizers’ formulation consists of sterile water 
combined with co-solvents if needed. It is prefera-
ble to keep the number of excipients present in the 
formulation to a minimum in order to avoid toxic-
ity [9].
The formulation of pMDIs consists of a product 
concentrate, which will be either solubilized or 
dispersed in a propellant using an elevated va-
pour pressure. The formulation itself is quite com-
plex, owing to the presence of both propellants 
and high vapour pressure [9]. Propellants can be 
liquefied compressed gas, compressed gas propel-
lants, or chlorofluorocarbons. However, due to 
their ozone-depleting behaviour, the use of chlo-
rofluorocarbons has been discontinued since Janu-
ary 1st, 1996, following the Montreal Protocol. 
They since have been replaced by hydrofluoroal-
kanes [52].
Out of the three main types of inhalation sys-
tems, DPIs would be the most advantageous type 
due to their propellant-free formulation. Howev-
er, DPIs’ formulation requires the use of micron-
ized drug particles. These particles display poor 
flow properties as well as cohesiveness. Increased 
Van der Waals, electrostatic forces, and surface 
tension between the layers of particles result from 
the high surface area to mass ratio caused by the 
micronized drug particles [9]. Because of this, 
their formulation usually requires the active phar-
maceutical ingredient to be combined with coarse 
and fine carrier particles. This will, in turn, ame-
liorate the flow properties and raise the particle 
aerodynamic behaviour [53].
The particle size of an aerosol plays a crucial 
role in delivering the drug to its target site, hence 
providing an efficient therapy, while simultane-
ously avoiding clearance mechanisms [54]. In fact, 
in aerosol therapy, the particle size is believed to be 
one of the most crucial physical characteristic [30]. 
In horses for instance, similarly as in humans, par-
ticles which are considered to be large (> 10 μm) 
are either separated and filtered in the upper re-
spiratory tract or collected in the larger airways. 
Particles which are considered to be medium-
sized (6-10 μm) will deposit and accumulate in the 
larynx, trachea, bronchi, and large diameter bron-
chioles. Particles which are considered to be small 
(5 μm or less) will deposit in the small-diameter 
bronchioles and alveoli; while roughly half of the 
particles which are considered to be very small 
(< 1 μm) will deposit in the alveoli, while the other 
half will be exhaled [30]. Therefore, powder for-
mulations intended for inhalation generally con-
tain micronized drug particles with a particle size 
between 1 and 5 μm in order to obtain a valuable 
central and deep lung deposition. These drug par-
ticles are usually blended with an inactive excipi-
ent of greater size (40μm). Possible inactive excipi-
ents are: lactose, mannitol, trehalose, sucrose, sor-
bitol, and glucose [55]. Among them, lactose (pre-
cisely a-lactose monohydrate) is the most fre-
quently used carrier owing to its numerous 
advantageous properties such as [56]:
 − Physico-chemical stability and compatibility 
(displayed with most low molecular weight 
drugs)
 − Safe toxicological profile
 − Availability and affordability
Nonetheless, lactose possesses disadvantages as 
well: it cannot be administered to patients who are 
diabetic or lactose-intolerant since it gets ultimate-
ly swallowed by the patient, due to its impact on 
the oropharynx following the device actuation 
[56]. Due to these reasons, mannitol can be used as 
an alternative to lactose [57]. It is also relevant to 
bear in mind that an active pharmaceutical ingre-
dient containing amino groups (proteins, weak 
bases) cannot be present in the same formulation 
as reducing sugars because it would lead to insta-
bility due to the Maillard reaction [58]. In order to 
overcome this, non-reducing disaccharides, non-
reducing polysaccharides (trehalose and raffinose, 
for instance), and other sugars are being investi-
gated as carriers [56].
Moreover, several active pharmaceutical ingre-
dients are highly potent: drugs used for the treat-
ment of diseases such as asthma are already effec-
tive at a low dose. For instance, only 200-400 μg 
for salbutamol and 6-12 μg for formoterol are re-
quired for the drug to be effective [59]. This arises 
issues concerning powder handling as well as pre-
cise metering of doses. In order to overcome those 
issues, carriers can be used.  The carrier material 
should meet requirements such as [56, 60]: 
 − Providing bulk and ensuring flowability
 − Decreasing the agglomeration of the particles
 − Facilitating powder handling and dosing by 
providing a larger volume to the formulation
 − Helping the dispersion of the micronized drug
Moreover, fine lactose particles present within 
an equivalent size range as the active pharmaceu-
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tical ingredient have been identified as an impor-
tant element in order to improve the formulation 
performance [61]. Among the possible explana-
tions for this phenomenon are the presence of ac-
tive sites and the agglomeration of drug and fine 
excipients [62]. Inhalation formulations containing 
a low dose of the active pharmaceutical ingredient 
tend to be more affected by the properties of the 
carrier. This might be due to the occurrence of ac-
tive sites on the carrier as well as their availability 
[60]. The drug/lactose ratio and the aerosolization 
performance are correlated, and this correlation is 
associated with the possible existence of active 
sites on the surface of the lactose carrier [63].
7.3. Carriers suitable for a small particle size
Powders suitable for inhalation are most common-
ly obtained by carrier-based systems which con-
sist of two elements: the drug and its carrier.
The drug is usually mixed with larger, coarser 
lactose particles which act as a carrier and amelio-
rate the dose reproducibility. As the drug and the 
carrier are blended, the micronized drug particles 
attach to the surface of the lactose carrier particles, 
hence forming an adhesive mixture (Figure 10).
Furthermore, interparticulate forces present in 
adhesive mixtures are required to be able to pro-
duce a blend which is stable and homogenous. 
Due to the considerable size difference between 
the drug and its carrier, the unplanned separation 
of the two should be avoided, while still enabling 
an easy detachment of one from the other through 
weak enough drug-carrier interactions. Conse-
quently, the drug delivery occurs through three 
steps [56]: the detachment of the active pharma-
ceutical ingredient from its carrier, their disper-
sion in the airflow, and the deposition in the respi-
ratory tract (Figure 11). In the case of DPIs, the 
powder formulation is present in the capsule in an 
aggregated form with a size of 100-150 μm. In or-
der to disaggregate it, a deep and strong inhala-
tion through the device is required, thus reducing 
it to inhalable particles (1-5 μm) which can suc-
cessfully deposit in the lungs [64]. This de-aggre-
gation process constitutes a fundamental require-
ment for DPIs capsules contents [65].
During the drug/carrier detachment in the first 
step, the fate of the carrier is either to remain in 
the inhalation device or to deposit in the oropha-
ryngeal region. In adhesive drug mixtures, excipi-
ents used as carriers are considered to have a 
“limited” loading capacity, which makes them 
convenient for low drug doses. Classic drug-to-
carrier ratios are 1:67.5 or 1:99 [56]. The drug 
quantity which can be processed is limited due to 
requirements for the content uniformity and sta-
bility [66]. The limit is set to 5-10% of the drug, de-
pending on the excipient used in the formulation 
as a carrier [67].
The use of active pharmaceutical ingredients at 
a low dose such as dry powders is mainly aimed 
for the therapy of respiratory diseases (asthma, 
COPD). In pulmonary drug delivery, the dose of a 
drug used is considered low when it is in the mi-
crogram range (<1 mg) [66]. The drug dose can 
vary from 6 μg (eformoterol 
fumarate: Oxis®) to 500 μg 
(fluticasone propionate: Flix-
otide®, Seretide®) [68].
8. Tests and characterization 
of aerosols
8.1. Tests
As seen previously, the for-
mulation of inhalation dosage 
forms plays a great role in 
their efficiency and is there-
fore quite elaborated. The 
processes it involves are com-
plex; thus thorough testing is 
necessary to ensure the safety 
and quality of the end prod-
uct. Table IV displays the gen-Figure 10 Adhesive mixture formation
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Figure 11 Illustration of the steps in the drug delivery of carrier-based formulations
Table IV Aerosol devices and formulations tests (based on [9, 69])
Test Description
Dose uniformity −− Assay of the material or the solvent onto which the dose is sprayed.
−− Firstly, an empty container is weighed. Secondly, a certain number of doses are sprayed in this 
same container, which is then weighed again. The difference in weight is then calculated, and 
divided by the number of doses sprayed. 
Particle size 
determination
The determination is done using a cascade impactor or using a light scattering decay method. 
The particle size is expressed in µm.
Moisture content The test can be done by Karl-Fischer or by gas chromatography. The moisture content is ex-
pressed in %.
Density The test can be done using a hydrometer or a pycnometer. A pressure tube is fitted with a Hoke 
valve, metal fingers, and a hydrometer placed into it. The sample is then put in through the Hoke 
valve. This causes the hydrometer to elevate in the pressure tube at half height. The density can 
then be read and is expressed in g/ml.
Vapor pressure The test can be done by pressure gauge. The pressure variation between containers indicates the 
presence of air in the headspace. Vapor pressure can also be accurately measured using a can 
punctuating device. The vapor pressure is expressed as kPa, bar, atm, or psi.
Spray pattern The aerosol being tested is sprayed on a paper coated with a dye-talc mixture. The dye is either 
water-soluble or oil-soluble. Particles which collide with the coated paper cause the dye to solu-
bilize and get absorbed onto the paper. This gives a definite spray pattern.
Aerosol valve discharge 
rate
Two weights are measured:  W1 and W2.
−− W1: Initial weight of a container
−− W2: Weight of that same container after being actuated for a particular period of time. 
The discharge rate with respect to time is obtained by dividing the difference in weights by the 
time (of the actuation process).
Propellant identification The identification can be done by gas chromatography or infrared spectrophotometry. These 
methods can also be used to determine the composition of a blend of propellants.
The determination of moisture, halogen, and non-volatile residue provide an acceptability and 




The test requires a Tag Open Cup (TOC) apparatus. The aerosol product is chilled to -25°F 
(= -31.67°C) then transferred to the apparatus. The temperature of the liquid is gradually 
increased. When the liquid’s vapor ignites, the “flash point” temperature has been reached. It is 
expressed in °C.
Flame projection The test measures the extension of a flame length when the aerosol product is sprayed on an open 
flame for about 4 seconds. A ruler is used to measure the extension of the flame, and the result 
is expressed in cm.
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eral and additional evaluation tests done on aero-
sols and their formulation [9, 69].
Characterization of the performance of DPIs 
can be done using two aspects: the patient’s inspi-
ratory flow and the turbulence generated inside 
the inhaler itself. Since DPIs are breath-actuated 
devices, the powder formulation they deliver re-
quires the patient to supply turbulent inspiratory 
forces to break down the powder aggregates into 
fine particles of less than 5 μm in diameter in or-
der for them to deposit deeper in the lungs. As 
mentioned before, optimal use of the dry powder 
inhaling device is determined by the patient pro-
viding an appropriate inspiratory flow, and the 
turbulence generated by the intrinsic resistance of 
the inhaler, which is influenced by the design of 
the device. Basically, three varieties of designs are 
available, with a low (such as the Breezhaler®), 
medium (such as the Ellipta®), or high resistance 
(such as the Handihaler®). The duplicability of the 
dose by the device at different flow rates demon-
strates how the incorrect manipulation of the in-
haler affects the system. The higher the inspirato-
ry flow, the better the performance of the device 
since the drug dose inhaled by the patient is in-
creased [70, 71]. A favourable peak inspiratory 
flow rate should be of minimum 60 L/min through 
the inhaler to achieve disaggregation of the pow-
der formulation. The device-specific airflow resis-
tance is determined using the pressure drop and 
the flow rate following Ohm’s law, as shown in 
equation (2) [72]. Higher airflow resistance is as-
sociated with more considerable difficulties for 
patients (particularly in children and elderly peo-
ple) to adequately operate the device with an ap-
propriate flow rate, which makes the airflow resis-
tant a significant parameter [70].
 (2) 
where  R = Resistance, ΔP = Pressure drop, 
Q = Flow rate.
Oxis Turbuhaler® and Foradil Aerolizer® DPIs 
have been tested in vitro to study their efficiency in 
delivering 12 μg of Formoterol fumarate, a 
β2-sympathomimetic drug, and 600 μg of lactose 
monohydrate. Four flow rates were investigated 
(28.3, 40, 60, and 80 L/min). The optimum flow rate 
for both inhalers ranges between 40 and 60 L/min 
to deliver a satisfactory bronchodilation effect. The 
study concluded that Oxis Turbuhaler® delivered 
smaller particles; thus a deeper lung deposition 
was achieved. However, the high specific airflow 
resistance is a factor which will affect the usage of 
the device by severe asthmatic children. Neverthe-
less, no difference in their bronchodilating effect 
was found [73].
8.2. Particle size determination
8.2.1. Cascade Impactor
The determination of the therapeutic activity of 
an inhalation aerosol is dependent on the particle 
size [69]. Cascade Impactors are mentioned in the 
Pharmacopeia and therefore constitute the most 
commonly used devices for the in vitro study and 
measurement of the particle size distribution of 
inhaled formulations. This is mainly due to their 
numerous advantages such as the direct measure-
ment of aerodynamic particle size, and the deter-
mination of drug mass in the formulation with 
different size ranges, without the disturbances 
from the excipients [17].
Originally, the Andersen Cascade Impactor 
(ACI) was the most commonly used impactor in 
the pharmaceutical industry. However, the ACI 
displayed certain disadvantages and has since 
been replaced by the Next Generation Impactor 
(NGI), specially designed for inhaler testing [74] 
(Figure 12).
Cascade impactors rearrange particles and drop-
lets in an aerosol based on their aerodynamic diam-
eter. They use particle/droplet inertia impaction to 
segregate particles and droplets from a moving air-
stream [69]. The NGI comprises 7 stages (Figure 
13), 5 of which are in a 0.5-5 microns range. Each 
stage contains a set of nozzles. The airflow moves 
Figure 12 Next Generation Impactor (NGI) with induction 
port and preseparator
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across the apparatus follow-
ing a sawtooth pattern. The 
velocity of the airstream is in-
creased as it is forced to cross 
through a sequence of nozzles 
comprising progressively de-
creasing jet diameters. This re-
sults in particle separation as 
well as sizing [74].
Another particular feature 
of the NGI is also its micro-
orifice collector (MOC). It 
catches highly small particles 
in a collection cup, which can 
be evaluated along with the 
particles collected in the stag-
es cups [75]. Aerodynamic 
properties can be calculated 
from the collected data.
Figure 14 shows the Spiri-
va HandiHaler® placed on the 
induction port of the NGI. 
HandiHaler is an 18 μm/cap-
sule DPI made by Boehringer 
Ingelheim/Pfizer Inc. Its pow-
der is delivered at a flow of 
20-30 L/min, making it a 
flow-limiting device [77, 78].
Figure 15 demonstrates the 
Serevent Evohaler® placed on 
the induction port of the NGI. 
Serevent Evohaler is a 25 μm/
actuation inhaler made by 
GlaxoSmithKline Inc. It is a 
CFC-free pMDI [79].
8.2.2. Laser Diffraction
Particle size analysis can also be performed using 
optical methods as an alternative, such as laser 
diffraction (light scattering), laser Doppler, or 
time-of-flight. The most widely used among these 
is the laser diffraction [17]. The Cascade Impactor 
analysis can be substituted by laser diffraction in 
order to assess the particle size, however, aerody-
namic diameters cannot be measured with this 
technique. Moreover, the main advantage offered 
by NGIs is the determination of the FPF and other 
size fractions. The other methods, such as laser 
diffraction provide no differentiation. It simply 
measures the overall particle size distribution in 
the sample [80]. However, laser diffraction is con-
sidered to be a remarkably accurate, flow rate-in-
dependent and a rather quick method and there-
fore constitutes an excellent alternative for the cas-
cade impactor measurements. This technique has 
been used since the 1980s to measure the particle 
size of nebulized drug solutions [81]. 
The laser produces a monochromatic, coherent, 
parallel beam which is widened by the beam ex-
pander unit (Figure 16). This beam then casts a 
light on the dispersed particles. The light pro-
duced is scattered by the dispersed particles. 
These particles in the measuring zone form scat-
tering patterns and these patterns carry informa-
tion on the number of particles, the particle size, 
and the particle shape in any orientation [82, 83]. 
Examples of laser diffraction instruments are:
Figure 13 NGI stages and micro-orifice collector (MOC) with their number of holes 
and nozzle diameter (based on [75, 76])
Figure 14 HandiHaler placed on the induction port of the NGI
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 −  RODOS for dry dispersions
 − HELOS (Helium-Neon Laser Optical System) la-
ser diffraction sensor which can be connected to 
different inhalers (DPI, MDI, Soft mist inhalers)
 − MYTOS which makes possible the in-line dry 
particle size analysis for automated laboratories
All are developed by Sympatec Inc. They pro-
vide a precise particle size analysis for dry pow-
ders in the size range below  0.1 μm to 4000 μm 
for RODOS, 0.1 μm to 8750 μm for HELOS, and 
from 0.25 μm to 3500 μm for MYTOS [84].
In the case of dry powders, sampling before mea-
suring is a significant step. An ineffective sampling 
technique will result in a wrong characterization of 
the powder. In laser diffraction, powder measure-
ments can be carried out by dry dispersion, which 
aim is to enable the measurement of particles indi-
vidually. This is done through the separation of par-
ticles agglomerates by suppressing the forces which 
bind these particles together. 
This can be achieved using the 
RODOS injection disperser 
(Sympatec Inc.). With RODOS, 
the compressed air injector 
provides an effective, long, and 
straight dispersion line of dry 
solid particles with a special 
flow control which can mix the 
particles with inert gas or com-
pressed air. This high airflow, 
the jet formation and expan-
sion provide an optimal aero-
sol cloud for the optical analy-
sis without aggregation. Mea-
surements directly from the 
aerosol cloud are also possible 
using systems such as HELOS 
(Sympatec Inc.), which pro-
vides a distribution analysis for 
powders and granules, but also 
wet samples such as suspen-
sions, emulsions, and sprays 
[80, 84].
However, this technique 
possesses drawbacks as well: 
the measuring zone lacks a 
suitable air extraction which 
would be required in order to 
prevent the aerosol droplets 
from entering back into the la-
ser beam. Air suction is also 
necessary to analyze how the 
inspiratory flow rate affects 
the droplet size distribution. This shortage is ex-
plained by the fact that a junction is needed be-
tween the nebulizer’s mouthpiece and the vacuum 
system in order to obtain a controlled air extrac-
tion. Nevertheless, it is not easily achievable and 
rather complicated to do so due to interferences 
with the laser beam. Other limitations include [80]:
 − The calculation of volume distribution curves 
presuming that the particles possess a spherical 
shape.
 − The inability to measure aerodynamic diame-
ters (geometric particle diameters are measured 
instead).
 − The inability to acquire fine particle mass frac-
tions.
 − The inability to measure low particle concentra-
tions (dose weights < 4 μg).
 − The inability to control the flow curve through 
the inhalation device.
Figure 15 Evohaler placed on the induction port of the NGI
Figure 16 Laser diffraction particle size analyzer layout (based on [82])
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 − Mixtures measurements (drug-drug or drug-ex-
cipients) are rather difficult.
 − The measuring range is broader than the drug 
particles’ size distribution: a 0.9 μm – 175 μm 
range for a 100 mm lens, and a 0.45 μm – 87.5 μm 
range for a 50 mm lens.
Nonetheless, laser diffraction remains a tech-
nique with several advantages, such as numer-
ous size classes, precision, and a brief measuring 
time.
8.3. Dissolution
The study of adissolution behaviour is the study 
of a solid substance’s potential to penetrate a sol-
vent medium based on affinity characteristics. 
This provides useful information on the sub-
stance’s absorption behaviour in vivo [17].
The dissolution profile of a dosage form consti-
tutes an essential parameter for the bioavailability 
of any drug that is applied by a non-parenteral 
route. Factors that influence the dissolution be-
haviour of a drug include drug solubility, drug 
dose, formulation properties, drug particle prop-
erties, and the epithelial lining fluid (ELF) compo-
sition (which changes along the respiratory tract) 
[85]. In the lungs, the dissolution is the most sig-
nificant in the small bronchioles and the alveoli, 
which constitute the segment where the majority 
of the drug absorption takes place. After inhala-
tion, the fate of the drug particles is to dissolve in 
the ELF present along the respiratory tract. The 
ELF consists of a surfactant layer and an aqueous 
phase [85]. According to the region of the lungs 
where it is situated, the lining fluid differs in com-
position, thickness, and volume: the trachea, bron-
chi, and bronchioles are enveloped with a thick 
mucus gel (approximately 3 – 23 μm) whereas the 
alveolar region is covered with a particularly thin 
film (approximately 0.07 μm). The progressing 
thinning of the ELF results in physiological dis-
similarities, which in turn induce difficulties in es-
tablishing the residence time of the particles by 
simulating lung conditions [86]. After inhalation, 
the particles which penetrate the non-ciliated seg-
ment of the pulmonary region will dissolve in the 
ELF. Only this dissolved portion of the dose ad-
ministered will be accessible for absorption 
through the alveolar membrane [17].
Currently, the pharmacopoeia does not list any 
standard method for the dissolution testing of in-
halation drugs despite the fact that several meth-
ods have been designed [17, 86, 87]. A certain 
number of methods are available to study conven-
tional solid dosage forms, but they are intended 
for the simulation of the gastrointestinal tract and 
are therefore not suitable to study the dissolution 
of inhaled drugs (mainly due to their “sink” con-
ditions”) [17]. An example of these methods is the 
paddle over disc dissolution setup. This method 
enables the evaluation of the in vitro dissolution 
rate of inhaled formulations [88]. Another method 
is the flow-through cell apparatus, which studies 
the dissolution profile of poorly soluble glucocor-
ticoids aerosols [89]. The dissolution profile of in-
haled formulations can also be assessed using the 
diffusion-Franz cell apparatus. A study evaluating 
these three methods (the paddle over disc meth-
od, the flow through cell, and the diffusion-Franz 
cell apparatus) concluded that the Franz cell ap-
paratus was the most promising [17, 90]. The 
Franz cell apparatus consists 
of a donor and receptor com-
partment. These two com-
partments are separated by a 
semi-permeable cellulose 
membrane. The powdered 
formulation is set on the bot-
tom surface of a filter mem-
brane, which is then posi-
tioned on the semi-permeable 
cellulose membrane. The 
drug will then dissolve and 
diffuse through the semi-per-
meable membrane. The study 
is done on samples gathered 
from the receptor compart-
ment. The dissolved drug 
which diffuses through the Figure 17 Franz Cell Model
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membrane is analyzed by collecting the samples 
from the acceptor compartment (Figure 17).
Moreover, developing a method for the dissolu-
tion testing of an inhaled drug applicable to the 
lungs and their physiology can be quite complex 
due to the lungs’ characteristics such as the small 
amount of their fluid. Besides, a separation of the 
API from the excipients should be done before 
testing [17]. However, a recent study developed 
an apparatus aiming to investigate the dissolution 
behaviour of anti-tubercular drugs powder for-
mulations. This apparatus consists of a flow per-
fusion cell which symbolizes the air/blood perfu-
sion. It employs a small volume of  25 μL of un-
stirred, stationary medium to study the in vitro 
dissolution of inhalable drug particles, notably 
moxifloxacin and ethionamide, two anti-tubercu-
lar drugs. The particles of these two drugs were 
set on a sheet glass with the help of a Twin Stage 
Impinger. The mucus in which they should dis-
solve was simulated by polyethylene oxide (PEO) 
in a phosphate-buffered saline (PBS). Their disso-
lution profile was then investigated. The study 
concluded that ethionamide has a lower solubility 
and displayed a slower dissolution rate than 
moxifloxacin under all the dissolution conditions 
applied. The dissolution behaviour of ethion-
amide brought into question the dissolution 
mechanisms in small volumes of stationary medi-
um (simulating the in vivo tracheobronchial region 
of the lungs). Such questions could be addressed 
using this method [17, 86, 88].
The tracheobronchial region of the respiratory 
tract is covered with a viscoelastic blend contain-
ing glycoproteins, proteins, and lipids. However, 
the composition of this mucus may vary in case of 
diseases [91]. In testing conditions, an accurate 
simulation of in vivo parameters is continuously 
required. In dissolution testing, it can be achieved 
through the use of biological simulated lung flu-
ids (SLF), which serve as dissolution media.
The SLF was first developed by Moss in 1979 
[92]. This simulated fluid provides a greater com-
prehension of in vivo mechanisms. However, as 
seen previously, the development of a standard-
ized dissolution method is a complex project due 
to the special characteristics of the lungs, such as 
the particularly small volume of fluid present. 
Despite that, research was done to study a pos-
sible reproducible, standardized test method to 
investigate the dissolution profile of a micronized 
hydrocortisone pulmonary formulation. This 
method includes a dissolution test station (with 
mini-paddles, dissolution vessels, a water bath, 
and a sampling probe) and a membrane cassette. 
Among other things, the influence of the SLF com-
position on the dissolution rate was investigated. 
A modified version of the SLF (mSLF) was also 
used, which consists of 100 ml of SLF + 200 μg/mL 
of 0.02% (w/v) of dipalmitoylphosphatidylcholine 
(DPPC). The samples of hydrocortisone in SLF 
and mSLF were examined using an HPLC system. 
The mSLF yielded an increase in the release rate of 
hydrocortisone because a DPPC-containing medi-
um may enhance the wettability of hydrophobic 
drugs and inhibit the aggregation of particles, 
therefore increasing the dissolution rate [88].
Another study designed a biorelevant SLF with 
distinct composition and characteristics (Table V), 
as well as directions for usage and storage [93].
Conclusion
Overall, it has been established that the pulmonary 
drug delivery demonstrates a significant relevance, 
notably due to the physiology of the lungs and 
their advantageous properties. Despite the pres-
ence of some disadvantages such as clearance 
mechanisms, pulmonary drug delivery continues 
to be a non-invasive route of administration that is 
preferred by patients. It has also been shown that 
pulmonary delivery is one of the oldest drug deliv-
ery methods. Since its first use, its application has 
gotten more and more elaborated. Nowadays, sev-
eral types of inhalation devices are available on the 
market: nebulizers, MDIs, and DPIs. Supplementa-
ry devices such as spacers are also employable in 
order to achieve optimal results. The performance 
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and effectiveness of such inhalation devices de-
pend partly on the particle size of the formulation 
used, as well as its deposition in the lungs. Such de-
position is achieved by several mechanisms: diffu-
sion, sedimentation, impaction, and interception. 
Furthermore, in order to assure the highest possi-
ble efficiency, formulations are developed follow-
ing several criteria. Therefore, thorough testing is 
required to ensure the safety and quality of the end 
product. These tests are performed on both the for-
mulation and the device which carries it. Investiga-
tions of the particle size and aerodynamic proper-
ties, for instance, can be done using laser diffrac-
tion and a cascade impactor.
Summing it up, the pulmonary drug delivery 
constitutes a considerably advantageous route of 
administration for local and systemic treatments 
of diseases. Nevertheless, the development of pul-
monary dosage forms is a complex process which 
requires extensive considerations and meticulous 
optimizing.
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